Pharmacy‐based triage to preselect high‐risk individuals for skin cancer screening: A pilot study Authors: An Buckinx, Laurence Feldmeyer, Philippa Golling, Carlo Mainetti, Cristina Mangas, Anja Wysocki, Véronique Del Marmol, Regina von Burg, Eva von Wartburg, Stephen P. Jenkinson, Daniel Hohl, Olivier Gaide Published: 2026 Dear Editor, Free skin cancer screening campaigns frequently attract health‐conscious individuals with limited risk factors, potentially limiting detection yield. 1 To evaluate whether community pharmacies could support the preselection of higher‐risk individuals, a pharmacy‐referral pathway was integrated into the 2025 Swiss National Skin Cancer Campaign. Pharmacists and pharmacy technicians across five cantons completed a standardized 60‐min online training delivered by dermatologists. The training covered the clinical relevance and visual recognition of features associated with increased skin cancer risk, including actinic keratoses (AK), solar lentigines, atypical naevi, high naevus count, increased wrinkles (solar elastosis, erythrosis interfollicularis colli, cutis rhomboidalis nuchae, Favre Racouchot syndrome), basal cell carcinoma (BCC), squamous cell carcinoma (SCC) and melanoma. Following this training, pharmacists referred individuals they considered at increased risk to the free screening day. All participants completed the EUSCAP questionnaire, 2 and dermatologists performing full‐body examinations with dermoscopy were blinded to the referral pathway. The primary outcome was detection of lesions suspicious for melanoma, BCC or SCC. A total of 523 participants were included in this analysis (473 self‐referred and 50 pharmacy‐referred), excluding one canton where no structured pharmacy‐referral pathway was implemented. The lower‐than‐expected number of pharmacy referrals likely reflects unauthorized access by self‐referred participants to reserved consultation slots. Due to this imbalance, a separate analysis of the Lucerne subset, which was more balanced, was performed and yielded similar results (data not shown). No significant differences in median age were observed between the self‐referred (public) and in the pharmacy‐referred (pharmacy) groups (Figure 1a), nor in sex distribution (Figure 1b). In the self‐referred group, 19 lesions suspicious for melanoma, BCC or SCC were identified in 473 participants (4.02%), compared with 6 such lesions in 50 participants (12.00%) in the pharmacy‐referred group (Figure 1c). The prevalence of AK was higher among pharmacy‐referred individuals (Figure 1d), while atypical naevi did not differ significantly between groups (Figure 1e). However, the combined lesion burden (the total number of actinic keratoses and atypical naevi) was significantly higher in pharmacy‐referred participants compared with self‐referred participants (p = 0.0002; Figure 1f). Solar lentigines were also more frequent in the pharmacy‐referred group (Figure 1g), despite similar age distributions. Finally, pharmacy‐referred individuals more frequently required dermatological follow‐up (Figure 1h). Presence of (pre)malignant lesions and risk factors in pharmacy‐referred versus general participants. (a) Median age did not differ between self‐referred (public) and pharmacy‐referred (pharmacy) participants. Mann–Whitney U test. (b) No significant differences were observed between the proportion of males or females in the self‐referred group and in the pharmacy‐referred group. Fisher's exact test. (c) The proportion of individuals with lesions suspicious for squamous cell carcinoma, basal cell carcinoma or melanoma was significantly higher in pharmacy‐referred individuals. Fisher's exact test, p < 0.05. (d) The proportion of individuals with actinic keratosis was significantly higher in pharmacy‐referred individuals. Fisher's exact test, p < 0.01. (e) The proportion of individuals with atypical naevi did not differ between the self‐referred group and the pharmacy‐referred group. Fisher's exact test. (f) The combined number of lesions (actinic keratoses and atypical naevi) was significantly higher in pharmacy‐referred individuals. Mann–Whitney U test. (g) The proportion of individuals with solar lentigines was significantly higher in the pharmacy‐referred group. Fisher's exact test, p < 0.05. (h) The proportion of individuals with a need for further dermatological follow‐up was significantly higher in the pharmacy‐referred group. Fisher's exact test, p < 0.01, ***p < 0.001. All analyses were conducted on raw datasets, with results presented as proportions to enhance clarity. AK, actinic keratosis, BCC, basal cell carcinoma, ns, not significant, SCC, squamous cell carcinoma. These findings suggest that pharmacy referral is associated with an increased detection of lesions suspicious for melanoma, BCC or SCC, as well as enrichment for visible markers of cumulative sun damage. However, several limitations must be acknowledged. Pharmacy‐referred participants represented a minority of the screened population, and referral uptake varied across cantons, resulting in group imbalance. Consequently, the study is underpowered to detect the true effect of pharmacy‐based triage on malignant lesion detection, and the observed differences should be interpreted as a trend rather than definitive evidence. Nevertheless, growing evidence supports an expanded role for community pharmacies in skin cancer prevention. In Belgium, pharmacy‐based counselling has engaged diverse populations and increased subsequent dermatologist consultations within 180 days. 3 In Spain, pharmacy‐led lesion assessment with digital imaging facilitated early identification of suspicious lesions and optimized dermatology referrals. 4 Within this context, our data suggest that trained pharmacists can identify individuals with visible sun damage and an increased likelihood of malignancy, supporting the plausibility of a triage approach. Diversifying recruitment pathways through structured pharmacy involvement may therefore represent a pragmatic strategy to improve risk stratification in national screening initiatives. Larger prospective studies with balanced groups are warranted to determine whether this approach can translate into a statistically significant increase in early malignant skin cancer detection. FUNDING INFORMATION The authors have nothing to report. CONFLICT OF INTEREST STATEMENT The authors declare no conflicts of interest. ETHICAL APPROVAL Our institution does not require an ethical approval for fully anonymized questionnaires and consultations performed during the free consultation of the Swiss national campaign for skin cancer. This study was conducted in accordance with the Helsinki principle and local ethical regulations. ETHICS STATEMENT Not applicable.